Table 1.
Characteristics of included trials.
| Included trials | Year | Study design | Country | Male | Age, (y) | LQ | Treatment duration | LQ formulation | LQ dosage | |
|---|---|---|---|---|---|---|---|---|---|---|
| No. (%) | Control | Intervention | No. (%) | Days | ||||||
| Chen J. J. [13] | 2020 | RCT | China | 38 (54.3) | 45.2 ± 4.7 | 44.8 ± 4.9 | 35 (50) | 15 | Capsules (0.35 g/capsule) | 4 capsules, bid |
| Yu P. [14] | 2020 | RCT | China | 171 (58.0) | 47.3 ± 8.7 | 48.3 ± 9.6 | 147 (49.8) | 7 | Granules (6 g/bag) | 6 g, tid |
| Chen C. W. [15] | 2021 | RCT | China | 35 (58.3) | 49.5 ± 5.1 | 50.2 ± 5.1 | 30 (50) | NA | Capsules (0.35 g/capsule) | 4 capsules, tid |
| Hu K. [16] | 2020 | RCT | China | 150 (52.8) | 51.8 ± 14.8 | 50.4 ± 15.2 | 142 (50) | 14 | Capsules (0.35 g/capsule) | 4 capsules, tid |
| Xiao M. Z. [17] | 2020 | RCT | China | 70 (57.9) | 53.9 ± 13.9 | 52.7 ± 14.0 | 58 (47.9) | 14 | Granules (6 g/bag) | 6 g, tid |
LQ: Lianhua Qingwen, RCT: randomized controlled trial, bid: bis in die, tid: ter in die.